Continuing Education Activity

The field of oncology continually evolves due to ongoing research and advancements in treatment modalities. Pemetrexed is a key chemotherapeutic agent used to treat various cancer types, including non-small cell lung cancer, mesothelioma, bladder cancer, breast cancer, and several other solid tumors. Understanding potential adverse effects, such as hematological toxicities, nephrotoxicity, and hypersensitivity reactions, is crucial for effective patient management and improved quality of life.

This clinical activity provides an overview of pemetrexed, including its indications, mechanisms of action, dosing information, infusion protocols, administration methods, and contraindications. Emphasis is placed on patient monitoring and other critical factors during pemetrexed therapy, supported by insights from recent clinical trials and research. The importance of staying informed about new formulations and emerging indications and the need for a patient-centered approach that considers individual patient characteristics, disease stage, and comorbidities are also highlighted.

Objectives:

• Differentiate between the mechanisms of action of pemetrexed and alternative chemotherapeutic agents to facilitate informed treatment decisions.
• Identify emerging indications and resistance mechanisms to optimize pemetrexed-based treatment approaches for patients with cancer.
• Implement the recommended monitoring protocols for patients undergoing pemetrexed therapy and strategies for effectively managing adverse effects.
• Develop collaboration between interdisciplinary healthcare team members to effectively manage pemetrexed therapy, assess treatment outcomes, and refine holistic cancer care plans for patients.

Indications

Pemetrexed is an antifolate metabolic inhibitor approved by the U.S. Food Drug Administration (FDA) in 2004 for the treatment of malignant pleural mesothelioma.[1][2] Pemetrexed was developed by Edward C. Taylor and his team at Princeton University, who first synthesized lometrexol, the prototypical de novo purine antimetabolite.[3] However, lometrexol's structure was unstable, requiring the C-6 chiral center to be replaced with a pyrrolopyrimidine ring, creating a new molecule: N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid. Eli Lilly and Company brought this medication to the market and gave it a brand name.[4] Pemetrexed is an antineoplastic agent that can be given as a single agent or as part of combination therapy.

FDA-Approved Indications

• Malignant pleural mesothelioma [2][5][6][7]

  • First-line treatment for stage I to stage IIIA, regardless of histologic type (as monotherapy)
  • First-line treatment for unresectable tumors, regardless of histologic type or patients who are not candidates for surgery (in combination with cisplatin)
  • As an adjuvant medication
• Non-small cell lung cancer (NSCLC), nonsquamous [8][9][10][11]

  • Locally advanced or metastatic, nonsquamous NSCLC (in combination with cisplatin)
  • Metastatic, nonsquamous NSCLC in patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations (in combination with platinum chemotherapy and pembrolizumab)
  • Maintenance treatment in patients whose disease has not progressed after 4 cycles of platinum-based chemotherapy
  • Patients with a history of prior chemotherapy (as monotherapy)

Off-Label Uses

Beyond its approved indications, pemetrexed has demonstrated effectiveness in treating other malignancies, highlighting its potential as a medication for managing challenging forms of cancer. Some of these are outlined below.

• Metastatic bladder cancer: Pemetrexed is used as monotherapy or in combination with cisplatin for metastatic transitional-cell bladder cancer.[12][13]

• Metastatic breast cancer: Pemetrexed is used as a first-line or second-line treatment for advanced or metastatic breast cancer.[14][15]

• Recurrent cervical cancer: Pemetrexed may be administered as a second-line treatment for recurrent or persistent cervical cancer.[16]

• Recurrent ovarian cancer: Pemetrexed is considered for recurrent or persistent platinum-resistant therapy of ovarian or primary peritoneal carcinoma.[1]

• Metastatic thymic malignancies: Pemetrexed is utilized as monotherapy in recurrent or metastatic thymoma or thymic carcinoma.[17][18]

Mechanism of Action

Pemetrexed inhibits the folate-dependent metabolic processes necessary for cellular replication. Specifically, it targets enzymes responsible for DNA and RNA synthesis, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT), and aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), which disrupts the synthesis of purines, pyrimidines, and proteins.[3] Pemetrexed is transported into cells via membrane carriers, where it is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. Polyglutamation is thought to occur more often in tumor cells than non-tumor cells. Polyglutamated metabolites have an increased intracellular half-life and prolonged drug action.[19]

Pharmacokinetics

The pharmacokinetics of pemetrexed comprise rapid intravenous (IV) administration, significant plasma protein binding, and renal metabolism. A thorough understanding of these pharmacokinetic characteristics facilitates this medication's safe and productive use in cancer therapy. With this understanding, healthcare providers can tailor dosing schedules and adeptly manage potential drug interactions or adverse reactions.[20]

Absorption: Pemetrexed is administered via intravenous (IV) formulation, bypassing the absorption phase. The IV infusion facilitates rapid and complete distribution of pemetrexed throughout the systemic circulation.

Distribution: Following IV administration, pemetrexed exhibits a steady-state volume of distribution of approximately 16.1 liters. Approximately 81% of the drug is bound to plasma proteins.

Metabolism: Pemetrexed is not metabolized to a significant extent.

Elimination: Pemetrexed is predominantly eliminated through renal excretion, with approximately 70% to 90% of the drug being excreted unchanged in the urine. In patients with consistent renal function, the total systemic clearance of pemetrexed is 91.8 mL/min, and its elimination half-life is approximately 3.5 hours. Pemetrexed is a substrate for organic anion transporter 3 (OAT3), a transporter protein primarily found in the kidney. This transporter is responsible for transporting pemetrexed from the bloodstream into renal tubular cells, facilitating its elimination from the body through urine.[21]

Administration

Available Forms and Strengths

Pemetrexed is available in 750 mg, 500 mg, 100 mg, and 1 mg formulations and may be administered intravenously in 25 mg/mL or 10 mg/mL concentrations.

Adult Dosage

The typical pemetrexed dose is 500 mg/m² every 3 weeks, depending on the indication. The clinician should always consult the drug package insert and institutional protocols before designing a dosing regimen for any patient. Pemetrexed is usually infused over 10 minutes, although this can vary depending on the specific indication or treatment protocol. When pemetrexed is part of a combination chemotherapy regimen, the exact administration order varies based on the protocol. Therefore, it is crucial to consult a protocol to determine the recommended sequence.

Before initiating pemetrexed therapy, it's recommended to start vitamin supplements to enhance their effectiveness and manage potential side effects. Premedication optimizes treatment outcomes while minimizing adverse effects, such as mucositis, gastrointestinal toxicity, and cutaneous reactions. Healthcare providers must monitor patients closely and adjust therapy based on individual responses.[22] A standard premedication regimen is outlined below. 

    Folic acid:

        Dosage: 400 to 1,000 μg orally once daily

        Start: 7 days before initiating pemetrexed therapy

        Duration: Throughout the treatment period and for 21 days after the final pemetrexed dose

    Vitamin B12:

        Dosage: 1,000 μg intramuscularly (IM) once

        Start: Administer once 7 days before initiating treatment

 Duration: Repeat every 3 therapy cycles

    Dexamethasone:

        Dosage: 4 mg orally twice daily

        Start: 24 hours before initiating pemetrexed therapy

        Duration: Administer twice daily for 3 days 

Specific Patient Populations

Hepatic impairment: Pemetrexed does not have any dose adjustments. Asymptomatic elevations of aspartate transaminase, alanine transaminase, and total bilirubin were observed during clinical trials; however, this did not affect the dose or schedule of pemetrexed administration.[23]

Renal impairment: Pemetrexed may increase toxic exposure in patients with kidney disease due to reduced plasma clearance. The recommended dose for a patient with a creatinine clearance (CrCl) ≥45 mL/min is 500 mg/m² on day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Patients with a CrCl of 45 to 60 mL/min may be at increased risk of hematologic, gastrointestinal, and kidney-related toxicity.[24] Using pemetrexed in patients with CrCl <45 mL/min is not recommended. Although pemetrexed may be removed through dialysis, it is not recommended for these patients.[25][26][27]

Pregnancy considerations: Based on animal studies and its mechanism of action, pemetrexed is not recommended during pregnancy due to its risk of causing fetal harm.[27]

Breastfeeding considerations: The presence or absence of pemetrexed in breast milk has not been established. Based on potential serious adverse effects, breastfeeding is not recommended during treatment and for 1 week after the last dose of pemetrexed.

Pediatric patients: The safety and efficacy of pemetrexed have not been established in pediatric patients.

Older patients: Clinical studies have revealed no differences between patients older and younger than 65. Refer to adult dosage.[28] 

Adverse Effects

Adverse effects associated with pemetrexed are primarily caused by dose-related toxicities. One of the most frequent adverse events is myelosuppression. Patients have a higher risk of myelosuppression if they are not administered vitamin supplementation before, during, and after undergoing pemetrexed therapy.[29]

The following common adverse effects are categorized by system.[30][31]

Hematology

• Anemia
• Neutropenia
• Thrombocytopenia

Generalized symptoms

• Fatigue

Gastrointestinal

• Nausea
• Vomiting
• Anorexia
• Constipation
• Mucositis
• Diarrhea
• Heartburn

Neurology

• Sensory neuropathy
• Taste disturbance

Dermatology

• Alopecia
• Rash

Drug Interactions

Patients who receive frequent chemotherapy infusions may use non-steroidal anti-inflammatories for pain control management. Clinicians should avoid administering ibuprofen to patients receiving pemetrexed. Both medications are eliminated renally. Pemetrexed is a substrate for organic anion transporter 3 (OAT3), and ibuprofen is an organic anion transporter 3 (OAT3) inhibitor. Concomitant use may increase the risk of nephrotoxicity, myelosuppression, and gastrointestinal toxicity. In patients with a creatinine clearance between 45 mL/min and 79 mL/min, it is recommended to avoid ibuprofen 2 days before the first dose of pemetrexed and up to 2 days after the final dose in a cycle.

When administered concurrently with nephrotoxic medications, there is a risk of prolonging the clearance time for pemetrexed. Simultaneous administration of other renally-eliminated substances may lead to a delay in clearance.[21]

Contraindications

Pemetrexed is contraindicated in patients with a history of severe hypersensitivity reactions. 

Box Warning and Precautions

Use caution in patients with a history of Stevens-Johnson syndrome or toxic epidermal necrolysis.[32] Pemetrexed should be used with caution in patients with pre-existing bone marrow suppression due to reported cases of severe myelosuppression. This medication may also cause nephrotoxicity, which may lead to renal failure. In patients with a history of pulmonary disease, severe interstitial pneumonitis has been reported. Other precautions for pemetrexed are radiation recall, teratogenicity, live vaccines, and increased risk of toxicity with ibuprofen.[21][33]

Monitoring

Patients receiving pemetrexed should be monitored with a complete blood count (CBC) with differential at day 1, 8, and 15 of each cycle. Female patients should be tested for pregnancy due to teratogenic properties. Before each cycle, baseline laboratory testing using renal function tests such as serum creatinine, creatinine clearance, blood urea nitrogen and total bilirubin, aspartate transaminase, and alanine transaminase should be obtained. Patients should also be monitored for adverse effects such as mucositis, pulmonary toxicity, dermatologic toxicity, and radiation recall. Pemetrexed should not be administered to patients with an absolute neutrophil count <1500 cells/mm³ or platelet count <100,000 cells/mm³. For nonhematologic toxicity grade 3 and above, pemetrexed should be held until the patient's CBC returns to baseline.[29]

Toxicity

Currently, no specific drugs are approved for the treatment of pemetrexed overdose. However, the data from animal studies suggests leucovorin may help alleviate the toxic effects associated with pemetrexed overdose. Symptoms of overdose include severe leukopenia, neutropenia (grade 4 lasting 3 days or more), and thrombocytopenia (grade 4). Additionally, leucovorin can be administered for bleeding associated with grade 3 thrombocytopenia and for managing grade 3 or 4 mucositis.[34]

Enhancing Healthcare Team Outcomes

The collaborative efforts of healthcare professionals in managing patients receiving pemetrexed are crucial for optimizing patient outcomes and ensuring the highest quality of care. Each healthcare team member plays a unique role in the care continuum, contributing their expertise to provide comprehensive support to patients and their families. Effective communication among team members promotes patient-centered care and facilitates seamless care coordination. Healthcare professionals can ensure patients receive the most appropriate and effective treatment while addressing their needs and preferences.

As frontline caregivers, nurses are pivotal in administering chemotherapy, monitoring patients for adverse reactions, and providing essential education and support throughout treatment. Their close interaction with patients positions them to identify signs and symptoms early, enabling timely intervention and improving patient safety.

With their specialized knowledge of medications and drug interactions, pharmacists are invaluable in optimizing medication regimens, minimizing adverse effects, and ensuring medication safety. Their collaboration with other healthcare professionals enhances the quality of care and contributes to better treatment outcomes.

Ethical considerations, such as informed consent and patient autonomy, must guide decision-making processes to uphold patients' rights and promote shared decision-making. Respecting patients' choices and preferences fosters trust and collaboration between healthcare professionals and patients, ultimately leading to better treatment adherence and outcomes.

Overall, multidisciplinary care guided by evidence-based practices, ethical principles, and effective communication is the cornerstone of successful cancer management with pemetrexed.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer. 2009 May;45(8):1415-23. [PubMed: 19168349]

2.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. [PubMed: 12860938]

3.

Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007 Feb;6(2):404-17. [PubMed: 17308042]

4.

Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M, Moran RG. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem. 1992 Nov 13;35(23):4450-4. [PubMed: 1447744]

5.

Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8. [PubMed: 16549838]

6.

Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013 Aug 06;109(3):552-8. [PMC free article: PMC3738125] [PubMed: 23860535]

7.

Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008 Jul;3(7):756-63. [PubMed: 18594322]

8.

Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M., TREAT investigators. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol. 2013 Apr;24(4):986-92. [PubMed: 23161898]

9.

Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg M, Treat J, Govindan R, Koustensis A, Barker S, Obasaju C. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer. 2015 Mar;87(3):232-40. [PubMed: 25650301]

10.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. [PubMed: 18506025]

11.

Karayama M, Inui N, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Suda T, Chida K. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study. Cancer Chemother Pharmacol. 2013 Aug;72(2):445-52. [PubMed: 23807323]

12.

Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006 Jul 20;24(21):3451-7. [PubMed: 16849761]

13.

Cao Y, He Y, Chen H, He S, Gu Y, Wang X, Chen B. Phase I study of gemcitabine-cisplatin versus pemetrexed cisplatin for patients with advanced or metastatic bladder cancer. J BUON. 2018 Mar-Apr;23(2):475-481. [PubMed: 29745095]

14.

Martin M, Spielmann M, Namer M, duBois A, Unger C, Dodwell D, Vodvarka P, Lind M, Calvert H, Casado A, Zelek L, Lluch A, Carrasco E, Kayitalire L, Zielinski C. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol. 2003 Aug;14(8):1246-52. [PubMed: 12881387]

15.

Llombart-Cussac A, Martin M, Harbeck N, Anghel RM, Eniu AE, Verrill MW, Neven P, De Grève J, Melemed AS, Clark R, Simms L, Kaiser CJ, Ma D. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res. 2007 Jun 15;13(12):3652-9. [PubMed: 17575230]

16.

Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol. 2010 Jan;21(1):61-6. [PubMed: 19605508]

17.

Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer. 2015 Jan;87(1):34-8. [PubMed: 25443273]

18.

Gbolahan OB, Porter RF, Salter JT, Yiannoutsos C, Burns M, Chiorean EG, Loehrer PJ. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma. J Thorac Oncol. 2018 Dec;13(12):1940-1948. [PubMed: 30121390]

19.

Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol. 2002 Dec;29(6 Suppl 18):3-17. [PubMed: 12571805]

20.

Ouellet D, Periclou AP, Johnson RD, Woodworth JR, Lalonde RL. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Cancer Chemother Pharmacol. 2000;46(3):227-34. [PubMed: 11021740]

21.

Posada MM, Bacon JA, Schneck KB, Tirona RG, Kim RB, Higgins JW, Pak YA, Hall SD, Hillgren KM. Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2015 Mar;43(3):325-34. [PubMed: 25504564]

22.

Singh N, Baldi M, Kaur J, Muthu V, Prasad KT, Behera D, Bal A, Gupta N, Kapoor R. Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial. Cancer. 2019 Jul 01;125(13):2203-2212. [PubMed: 30825389]

23.

Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol. 2002 May;13(5):737-41. [PubMed: 12075742]

24.

Rusch VW. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol. 2003 Jul 15;21(14):2629-30. [PubMed: 12860935]

25.

Hill J, Vargo C, Smith M, Streeter J, Carbone DP. Safety of dose-reduced pemetrexed in patients with renal insufficiency. J Oncol Pharm Pract. 2019 Jul;25(5):1125-1129. [PubMed: 29871545]

26.

Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006 Feb 01;24(4):552-62. [PubMed: 16391300]

27.

de Rouw N, Croes S, Posthuma R, Agterhuis DE, Schoenmaekers JJAO, Derijks HJ, Burger DM, Dingemans AM, Ter Heine R. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. Lung Cancer. 2019 Apr;130:156-158. [PubMed: 30885337]

28.

Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Kurata T, Gray JE, Schwarzenberger P, Jensen E, Pietanza MC, Rodríguez-Abreu D. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 Apr 10;41(11):1992-1998. [PMC free article: PMC10082311] [PubMed: 36809080]

29.

Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004 Apr;5 Suppl 2:S51-5. [PubMed: 15117425]

30.

Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. [PubMed: 22341744]

31.

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 01;22(9):1589-97. [PubMed: 15117980]

32.

Pierard-Franchimont C, Lesuisse M, Humbert P, Delvenne P, Pierard GE. Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf. 2012 Nov 01;7(5):357-60. [PubMed: 23373549]

33.

Kim KH, Song SY, Lim KH, Han SS, Kim SH, Cho JH, Park CW, Lee S, Lee HY. Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer. Cancer Res Treat. 2013 Mar;45(1):74-7. [PMC free article: PMC3629367] [PubMed: 23613674]

34.

Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Muñoz M, Reck M. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol. 2007 Mar;2(3):221-9. [PubMed: 17410045]

Disclosure: Iliana Ramos Morales declares no relevant financial relationships with ineligible companies.

Disclosure: Matthew Yacobucci declares no relevant financial relationships with ineligible companies.

Disclosure: Conor Sheehy declares no relevant financial relationships with ineligible companies.